docj, since we don't get play by play from the company, we are limited to speculation. That is almost always the case with microcap biotech. However, we now have a CEO who has a long clinical and professional relationship with Cytodyn and Leronlimab. I choose to believe that he and the team are lining up their ducks in order to submit articles, develop protocols for studies, and arrange funding. Silence does not mean nothing is happening, but that real work is occurring behind the scene. I could be wrong, but this is the only approach that makes sense to me.

I posted the WSJ article because battling inflammation and enhancing the immune system is at the core of the LL platform. I have no expertise in these areas other than what I read here. If LL addresses multiple causes of inflammation, Ohm's list of conditions will grow exponentially. OTOH, it has to be time-consuming to sort out priorities, especially those priorities that will attract partners and/or funding.

The pps has very little relevance to LL's potential, IMO. When previous management PR'd their progress, real and aspirational, investors jumped on the train. $10 to .14 is an investing disaster. It's going to take real science and statistically significant results to regain the confidence of those investors and potential partners and get them back on the train. I'll leave it to others to explain the outside influences that may affect the share price.